Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00949325 · OUTCOME

Time to Response

Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma · Source last updated 2019-03-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
up to 5 years

What was measured

Number of days after 2 cycles of treatment, until maximal response is observed.

Analysis population: Although the original protocol specified that "time to maximal response" would be an outcome measure that would be obtained, appropriate data were not collected, so this outcome measure cannot be evaluated or reported.

Groups in this outcome

Subjects Who Were Treated at the Temsirolimus MTD, 20 mg/m^2

Not reported

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Subjects Who Were Treated at the Temsirolimus MTD, 20 mg/m^20

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Number of days after 2 cycles of treatment, until maximal response is observed.
groups
  1. id
    OG000
    title
    Subjects Who Were Treated at the Temsirolimus MTD, 20 mg/m^2
population Description
Although the original protocol specified that "time to maximal response" would be an outcome measure that would be obtained, appropriate data were not collected, so this outcome measure cannot be evaluated or reported.
reporting Status
POSTED
time Frame
up to 5 years
title
Time to Response
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice